Last reviewed · How we verify

Loceryl Nail Lacquer

Galderma R&D · FDA-approved active Small molecule

Amorolfine inhibits fungal sterol synthesis by blocking lanosterol demethylase, disrupting the integrity of the fungal cell membrane.

Amorolfine inhibits fungal sterol synthesis by blocking lanosterol demethylase, disrupting the integrity of the fungal cell membrane. Used for Onychomycosis (fungal nail infection) caused by dermatophytes, yeasts, and non-dermatophyte molds.

At a glance

Generic nameLoceryl Nail Lacquer
Also known asLoceryl NL
SponsorGalderma R&D
Drug classMorpholine antifungal
TargetLanosterol 14α-demethylase (CYP51)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Amorolfine is a morpholine antifungal that targets the cytochrome P450-dependent enzyme lanosterol 14α-demethylase in the ergosterol synthesis pathway. By inhibiting this enzyme, it causes depletion of ergosterol and accumulation of toxic sterol precursors, leading to fungal cell membrane dysfunction and cell death. This mechanism is effective against dermatophytes, yeasts, and other fungi causing onychomycosis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: